We demonstrated that the drug combination effectively decreased cyclin expression, induced p21Cip1 and p27Kip1, and caused G2/M cell cycle arrest, suggesting that the combination of OTS167 and RGB-286638 preferentially targets the molecules associated with ACC aggressiveness. The gene discussed is CDKN1A; the disease is adrenal cortex carcinoma.